Please assess the completion status of the following clinical trial:

Trial Title: Metformin Plus Megestrol Acetate As a Fertility-sparing Treatment in Patients with Atypical Endometrial Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-45 years old;~2. pathologically diagnosed with AEH for the first time;~3. desire to preserve their fertility;~4. no signs of suspicious myometrial invasion or extrauterine metastasis by enhanced magnetic resonance imaging (MRI), enhanced computed tomography (CT) or transvaginal ultrasonography (TVUS);~5. no contraindication for metformin, megestrol acetate or pregnancy;~6. no hormone or metformin treatment within 6 months before entering the trial;~7. not pregnant when participating in the trial;~8. willing to follow the trial arrangement after being fully informed of all the risks and inconveniences caused by the trial.~Exclusion Criteria:~Patients who had one or more of the following conditions:~1. allergy history or contraindications for megestrol acetate or metformin;~2. pregnant when initiating the study;~3. alcoholism, severe infection, severe chronical diseases (dysfunction of heart, liver, lung or kidney);~4. high risk of thrombosis;~5. recurrent AEH;~6. endometrial cancer;~7. other malignancy history.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Metformin plus megestrol acetate (Type: EXPERIMENTAL): Metformin 1500mg per day plus megestrol acetate 160mg per day.
- Megestrol acetate (Type: ACTIVE_COMPARATOR): Megestrol acetate 160mg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).